Year-to-date obesity drug sales at Novo Nordisk surpass all of 2020

Novo Nordisk obesity drugs Saxenda and Wegovy have sold for DKK 5.9bn (USD 919m) in the first three quarters of the year, surpassing the full-year sales last year.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Sales of Novo Nordisk's obesity drugs have continued their upward momentum, Wednesday's quarterly report from the pharmaceutical company shows.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs